JP3148243B2 - 総コレステロールおよび低密度リポタンパク質コレステロールの血中レベルを減少させる方法 - Google Patents

総コレステロールおよび低密度リポタンパク質コレステロールの血中レベルを減少させる方法

Info

Publication number
JP3148243B2
JP3148243B2 JP50826894A JP50826894A JP3148243B2 JP 3148243 B2 JP3148243 B2 JP 3148243B2 JP 50826894 A JP50826894 A JP 50826894A JP 50826894 A JP50826894 A JP 50826894A JP 3148243 B2 JP3148243 B2 JP 3148243B2
Authority
JP
Japan
Prior art keywords
hmb
cholesterol
ldl
low density
density lipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP50826894A
Other languages
English (en)
Japanese (ja)
Other versions
JPH08501777A (ja
Inventor
ニッセン、スティーヴン・エル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iowa State University Research Foundation Inc ISURF
Original Assignee
Iowa State University Research Foundation Inc ISURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3148243(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iowa State University Research Foundation Inc ISURF filed Critical Iowa State University Research Foundation Inc ISURF
Publication of JPH08501777A publication Critical patent/JPH08501777A/ja
Application granted granted Critical
Publication of JP3148243B2 publication Critical patent/JP3148243B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP50826894A 1992-09-16 1993-09-15 総コレステロールおよび低密度リポタンパク質コレステロールの血中レベルを減少させる方法 Expired - Lifetime JP3148243B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94640492A 1992-09-16 1992-09-16
US946,404 1992-09-16
US07/946,404 1992-09-16
PCT/US1993/008695 WO1994006417A1 (en) 1992-09-16 1993-09-15 Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol

Publications (2)

Publication Number Publication Date
JPH08501777A JPH08501777A (ja) 1996-02-27
JP3148243B2 true JP3148243B2 (ja) 2001-03-19

Family

ID=25484425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50826894A Expired - Lifetime JP3148243B2 (ja) 1992-09-16 1993-09-15 総コレステロールおよび低密度リポタンパク質コレステロールの血中レベルを減少させる方法

Country Status (12)

Country Link
US (1) US5360613A (Direct)
EP (1) EP0660706B1 (Direct)
JP (1) JP3148243B2 (Direct)
AU (1) AU673002B2 (Direct)
BR (1) BR9307035A (Direct)
CA (1) CA2142314C (Direct)
DE (1) DE69327468T2 (Direct)
ES (1) ES2142353T3 (Direct)
FI (1) FI951218A7 (Direct)
NO (1) NO951000D0 (Direct)
NZ (1) NZ256300A (Direct)
WO (1) WO1994006417A1 (Direct)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
AU2620600A (en) * 1999-01-21 2000-08-07 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
JP4166580B2 (ja) * 2001-05-18 2008-10-15 ロンザ ア−ゲ− ３−ヒドロキシ−３−メチル酪酸ナトリウムの固体組成物の製造方法
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
WO2005096846A1 (en) * 2004-03-11 2005-10-20 Wiley Organics, Inc. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP1973426A2 (en) * 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions for preventing and reducing delayed onset muscle soreness
JP5227182B2 (ja) 2005-12-19 2013-07-03 アボット・ラボラトリーズ １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
US9770424B2 (en) 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
EP3403516A1 (en) 2008-12-09 2018-11-21 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11042605B2 (en) 2009-07-21 2021-06-22 Ccqcc Corp. Method and apparatus for calibration and testing of scientific measurement equipment
US8538727B2 (en) * 2009-07-21 2013-09-17 George S. Cembrowski Method and apparatus for calibration and testing of scientific measurement equipment
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
US8916217B2 (en) 2010-01-29 2014-12-23 Abbott Laboratories Aseptically packaged nutritional liquids comprising HMB
RU2012125881A (ru) 2010-01-29 2014-03-10 Эбботт Лэборетриз Питательные эмульсии, содержащие бета-гидрокси-бета-метилбутират кальция (гмб кальция)
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
CA2841748C (en) * 2011-07-15 2021-06-15 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
EP2744489A4 (en) * 2011-08-15 2015-03-18 Abbott Lab PROCESS FOR THE PREPARATION OF HMB AND SALTS FROM THEREOF
EP2773363A1 (en) 2011-11-03 2014-09-10 University of Florida Research Foundation, Inc. Nutritional supplement for weight management
WO2012140276A2 (en) * 2011-11-17 2012-10-18 Lonza Ltd Process for the preparation of 3-hydroxy-3-methylbutyric acid or its calcium salts
PL3733171T3 (pl) 2012-09-10 2024-03-18 Metabolic Technologies, LLC Kompozycje zawierające hmb i atp oraz ich zastosowanie
EP3122348B1 (en) 2014-03-27 2020-05-27 Winterfield, Roland, W. Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
ES2973467T3 (es) 2015-09-16 2024-06-20 Metabolic Tech Llc Composiciones y métodos de uso de beta-hidroxi-beta-metilbutirato (HMB) para mejorar la recuperación de trauma de tejidos blandos
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
ES2899261T3 (es) * 2015-11-19 2022-03-10 Kyowa Hakko Bio Co Ltd Cristales de una sal de un catión monovalente de ácido 3-hidroxiisovalérico y método para producir dichos cristales
BR112018014920A2 (pt) 2016-01-21 2018-12-18 Metabolic Tech Inc métodos de autofagia por modulação, de tratamento ou redução da probabilidade do início de uma condição mediada por autofagia, de tratamento, inibição, redução, diminuição, ou prevenção de um distúrbio relacionado à idade, de modulação da expressão ou atividade de pelo menos um fator de transcrição, de tratamento, prevenção, diminuição, inibição ou redução de uma condição patológica atribuível a um estado de excesso de nutriente, de promoção de longevidade por autofagia por modulação, de aumento da duração de tempo que um mamífero pode levar um estilo de vida ativo sem sofrer de condições associadas com envelhecimento e de prolongamento do período de saúde de um mamífero.
SG11201811493UA (en) 2016-06-24 2019-01-30 Otsuka Pharma Factory Inc Crystal of amino acid salt of 3-hydroxyisovaleric acid and production method thereof
CA3041520A1 (en) 2016-10-21 2018-04-26 Metabolic Technologies, Inc. Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) and probiotics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629449A (en) * 1968-04-22 1971-12-21 Majid Siddiqi Process of combatting hypercholesterolemia
US4764531A (en) * 1986-03-11 1988-08-16 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to laying chickens
US4760090A (en) * 1986-03-11 1988-07-26 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to cattle and sheep
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals

Also Published As

Publication number Publication date
FI951218A0 (fi) 1995-03-15
JPH08501777A (ja) 1996-02-27
AU4922593A (en) 1994-04-12
EP0660706B1 (en) 1999-12-29
ES2142353T3 (es) 2000-04-16
FI951218L (fi) 1995-03-15
DE69327468T2 (de) 2000-05-11
FI951218A7 (fi) 1995-03-15
NZ256300A (en) 1997-06-24
NO951000L (no) 1995-03-15
AU673002B2 (en) 1996-10-24
WO1994006417A1 (en) 1994-03-31
CA2142314A1 (en) 1994-03-31
US5360613A (en) 1994-11-01
CA2142314C (en) 1999-06-01
EP0660706A1 (en) 1995-07-05
BR9307035A (pt) 1999-06-29
NO951000D0 (no) 1995-03-15
DE69327468D1 (de) 2000-02-03
EP0660706A4 (Direct) 1995-07-26

Similar Documents

Publication Publication Date Title
JP3148243B2 (ja) 総コレステロールおよび低密度リポタンパク質コレステロールの血中レベルを減少させる方法
JP2925326B2 (ja) ヒトの窒素保持の促進方法
JP2894832B2 (ja) 赤肉組織の成長を増加させるための食用肉生産動物を飼育する方法
ES2204142T3 (es) Nuevos analogos grasos para el tratamiento de la diabetes.
Blesbois et al. Effect of dietary fat on the fatty acid composition and fertilizing ability of fowl semen
JP3390846B2 (ja) バイオマスの利用
US4992470A (en) Method of enhancing immune response of mammals
EP1196161B1 (en) Conjugated linoleic acid for treatment of cyclooxygenase-2 mediated inflammation and pain
Friedman et al. Effect of dietary fatty acids on antibody production and fatty acid composition of lymphoid organs in broiler chicks
JPH04230624A (ja) 犬の加齢による認知機能障害を治療する方法
EA025256B1 (ru) Композиция, подходящая для лечения нарушений липидного обмена
JPH03500007A (ja) 飼いならした犬及び猫における食餌誘因カルニチン欠乏の防止法
JPH11193296A (ja) 抗肥満剤及び脂質代謝改善剤
JPH06101988B2 (ja) 飼料の改良利用と畜肉組成向上とのための或種の化合物の生長促進剤としての家畜飼料への添加使用
JP2003500362A (ja) 免疫反応の調節および炎症性疾患の治療のための方法および組成物
US4937077A (en) Method for improving feed conversion of meat-producing animals by oral administration of 2-deoxy-D-hexose
Noble et al. Effects of a commercial dose of L‐tryptophan on plasma tryptophan concentrations and behaviour in horses
JP2001172180A (ja) アポｂ分泌／ｍｔｐ阻害剤の使用
EP1143945B1 (en) Carnitine supplemented diet to prevent sudden death syndrome in broiler breeder type poultry
Shaklee Research on cholesterol in poultry and eggs in the United States
Dobenecker et al. 306 Oral therapy with specific bioactive collagen peptide (BCP) improves gait and quality of life in canine osteoarthritis patients
JPS61151129A (ja) ビタミンｅ吸収促進剤
TARKA JR A toxicological evaluation of foods containing methylxanthines with emphasis on cocoa
US20040018224A1 (en) Supplementation of the diet with cholesterol results in a large stimulation of the plasma omega-3 fatty acid content
Al-Shebib et al. Experimental study of the effects on rabbits of the injectable contraceptive medroxyprogesterone acetate, cholesterol feeding and drug-atherogenic diet combination

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090112

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090112

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100112

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110112

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120112

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130112

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130112

Year of fee payment: 12